Visit https://www.peervoice.com/DYY860 to view the entire programme with slides. After completing “Current and Emerging Radiopharmaceuticals for Prostate Cancer: Is There a Role for Both?”, participants will be able to: Explain the rationale for radiopharmaceuticals as active lines of treatment for men with metastatic prostate cancer (mPC); Appraise how the clinical data and real-world evidence for radiopharmaceuticals may inform the individualised management of men with mPC now and in the future; Propose individualised treatment plans for men with mPC who are suitable for radiopharmaceuticals.